BioGend Therapeutics Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was TWD 485,000 compared to TWD 741,000 a year ago. Operating loss was TWD 64.185 million compared to TWD 76.004 million a year ago. Net loss was TWD 70.113 million compared to TWD 74.234 million a year ago. Basic loss per share was TWD 0.85 compared to TWD 0.92 a year ago.